Jakavi 5mg

Description

Jakavi 5mg (56 tablets) contains ruxolitinib,

a kinase inhibitor used to treat myelofibrosis and Jakavi 5mg  ONLINE polycythaemia vera by reducing spleen size and blood cell counts.

These white, round tablets are taken orally, typically twice Jakavi 5mg  PRICE daily. Common side effects include bruising, anemia, and infections. Full BUY ONLINE Jakavi 5mg prescribing info.

Ruxolitinib is a Janus kinase inhibitor. This drug is developed and marketed by Incyte Corp in the United States under the trade name Jakafi, and outside the US, it is branded as Jakavi, marketed by Novartis.

Myelofibrosis (MF): Used for treating disease-related enlarged spleen or symptoms in adult patients (primary, post-polycythemia vera, or post-essential thrombo cythemia MF).Polycythemia Vera (PV): Used for adult patients who show resistance or intolerance towards hydroxyurea.Graft-Versus-Host Disease (GvHD): Used for acute or chronic GvHD in patients showing inadequate response to corticosteroids.

Pathways: It acts as a selective inhibitor of the Janus Associated Kinases (JAKs), especially JAK1 and JAK2, which mediate signaling for cytokines and cell proliferation.Function: Under the condition of diseases like MF and PV, there is a malfunction in the JAK-STAT pathway. The ruxolitinib suppresses the hyperactivity in the pathway resulting in a decrease in tumor cell growth, excess production of blood cells and reduction of constitutional symptoms.

Jakavi is used in the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombo cythaemia myelofibrosis.Jakavi is the first targeted treatment to be approved by the European Commission for these indications.